Insider Trading Activity Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) – SVP Sold 350 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Bruce Leicher , SVP of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) reportedly Sold 350 shares of the company’s stock at an average price of 16.6 for a total transaction amount of $5,810.00 SEC Form

Insider Trading History For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

On 2/15/2013 Bruce Leicher, SVP, sold 1,040 with an average share price of $12.26 per share and the total transaction amounting to $12,750.40.View SEC Filing

On 3/5/2013 Elizabeth Stoner, Director, sold 2,040 with an average share price of $14.00 per share and the total transaction amounting to $28,560.00.View SEC Filing

On 5/15/2013 Craig A Wheeler, President, sold 1,687 with an average share price of $13.33 per share and the total transaction amounting to $22,487.71.View SEC Filing

On 5/21/2013 Craig A Wheeler, President, sold 2,109 with an average share price of $12.83 per share and the total transaction amounting to $27,058.47.View SEC Filing

On 5/23/2013 Craig A Wheeler, President, sold 2,109 with an average share price of $13.03 per share and the total transaction amounting to $27,480.27.View SEC Filing

On 6/19/2013 Richard P Shea, CFO, sold 21,550 with an average share price of $14.61 per share and the total transaction amounting to $314,845.50.View SEC Filing

On 6/27/2013 Richard P Shea, CFO, sold 10,522 with an average share price of $14.61 per share and the total transaction amounting to $153,726.42.View SEC Filing

Analyst Ratings For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
These are 1 Sell Rating, 4 Hold Ratings, 2 Buy Ratings .
The current consensus rating for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is Hold (Score: 2.14) with a consensus target price of $16.71 , a potential (2.86% upside)

Analyst Ratings History For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

On 8/24/2015 Sanford C. Bernstein Reiterated Rating Buy
On 6/6/2016 Goldman Sachs Group, Inc. (The) Initiated Coverage of rating Neutral with a price target of $14.00
On 8/5/2016 Brean Capital Set Price Target of rating Buy with a price target of $19.00
On 11/3/2016 J P Morgan Chase & Co Reiterated Rating Buy with a price target of $18.00
On 2/21/2017 Leerink Swann Downgraded rating Outperform to Market Perform with a price target of $18.00 to $18.00
On 5/3/2017 Aegis Reiterated Rating Hold with a price target of $17.00
On 5/3/2017 Cowen and Company Reiterated Rating Hold with a price target of $15.00

Recent Trading Activity for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Shares of Momenta Pharmaceuticals, Inc. closed the previous trading session at 16.25 up +0.35 2.20% with 746,780 shares trading hands.